285 related articles for article (PubMed ID: 29358291)
1. Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock.
Borsuk-De Moor A; Rypulak E; Potręć B; Piwowarczyk P; Borys M; Sysiak J; Onichimowski D; Raszewski G; Czuczwar M; Wiczling P
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358291
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H
Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock.
Masich AM; Kalaria SN; Gonzales JP; Heil EL; Tata AL; Claeys KC; Patel D; Gopalakrishnan M
Pharmacotherapy; 2020 Mar; 40(3):211-220. PubMed ID: 31957057
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?
Heffernan AJ; Germano A; Sime FB; Roberts JA; Kimura E
Eur J Clin Pharmacol; 2019 Sep; 75(9):1219-1226. PubMed ID: 31154476
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
[TBL] [Abstract][Full Text] [Related]
9. Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia.
Dimopoulos G; Almyroudi MP; Kapralos I; Apostolopoulou O; Flevari A; Nicolau DP; Dokoumetzidis A
Int J Antimicrob Agents; 2022 Jan; 59(1):106487. PubMed ID: 34843925
[TBL] [Abstract][Full Text] [Related]
10. Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections.
Bastida C; Hernández-Tejero M; Cariqueo M; Aziz F; Fortuna V; Sanz M; Brunet M; Fernández J; Soy D
J Antimicrob Chemother; 2022 Apr; 77(5):1365-1371. PubMed ID: 35178567
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
12. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
[TBL] [Abstract][Full Text] [Related]
14. Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Ordóñez Mejia JL; Roberts MS; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4577-84. PubMed ID: 27185798
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?].
Brinkmann A; Röhr AC; Köberer A; Fuchs T; Preisenberger J; Krüger WA; Frey OR
Med Klin Intensivmed Notfmed; 2018 Mar; 113(2):82-93. PubMed ID: 27624768
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy.
Carlier M; Taccone FS; Beumier M; Seyler L; Cotton F; Jacobs F; Roberts JA
Int J Antimicrob Agents; 2015 Oct; 46(4):413-9. PubMed ID: 26208469
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock.
Vázquez M; Fagiolino P; Boronat A; Buroni M; Maldonado C
Int J Clin Pharmacol Ther; 2008 Mar; 46(3):140-5. PubMed ID: 18397685
[TBL] [Abstract][Full Text] [Related]
18. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability.
Kapralos I; Mainas E; Apostolopoulou O; Siopi M; Neroutsos E; Apostolidi S; Dimopoulos G; Sambatakou H; Valsami G; Meletiadis J; Dokoumetzidis A
Br J Clin Pharmacol; 2021 Mar; 87(3):1024-1032. PubMed ID: 32633039
[TBL] [Abstract][Full Text] [Related]
20. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial.
De Winter S; Wauters J; Meersseman W; Verhaegen J; Van Wijngaerden E; Peetermans W; Annaert P; Verelst S; Spriet I
Int J Antimicrob Agents; 2018 Apr; 51(4):562-570. PubMed ID: 29180278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
